The association of these three mutations with reduced RRAS2 mRNA expression and diminished lymphocytosis reinforces the idea that RRAS2 overexpression is implicated in CLL development and disease progression. The gene discussed is RRAS2; the disease is B-cell chronic lymphocytic leukemia.